CDI cross-linked β-cyclodextrin nanosponges of paliperidone: synthesis and physicochemical characterization

Abstract

Paliperidone (PLP) is an antipsychotic drug indicated for treatment and management of schizophrenia. The current study demonstrates potential of PLP-loaded β-cyclodextrin-based nanosponges (CDNS) for solubility enhancement and prolonged release of PLP. The inclusion complexes of PLP with carbonyldiimidazole (CDI) cross-linked nanosponges were synthesized. The drug-loaded CDNS were characterized for particle size, zeta potential, encapsulation efficiency, stability study, in vitro drug release studies. The interaction of PLP with CDNS was ascertained by FTIR, DSC and PXRD studies. The particle size and zeta potential values were sufficient to obtain stable formulations. Solubility was significantly increased and in vitro drug release studies revealed prolonged release of PLP from the CDNS for 6 h. PXRD study revealed that the crystallinity of PLP was decreased due to complexation with the CDNS. Thus, cyclodextrin-based nanosponges represent a novel approach for solubility enhancement and improved dissolution of selected model drug PLP.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. 1.

    Arima H, Hayashi Y, Higashi T, Motoyama K. Recent advances in cyclodextrin delivery techniques. Expert Opin Drug Deliv. 2015;12:1425–41.

    Article  Google Scholar 

  2. 2.

    de Miranda HGFJC, de Azevedo Martins TE, Veiga F. Cyclodextrins and ternary complexes: technology to improve solubility of poorly soluble drugs. Brazilian J Pharm Sci. 2011;47:665–61.

    Article  Google Scholar 

  3. 3.

    Loftsson T, Magnúsdóttir A, Másson M, Sigurjonsdottir JF. Self-association and cyclodextrin solubilization of drugs. J Pharm Sci. 2002;91:2307–16.

    CAS  Article  Google Scholar 

  4. 4.

    Caldera F, Tannous M, Cavalli R, Zanetti M, Trotta F. Evolution of cyclodextrin nanosponges. Int J Pharm. 2017;531:470–9.

    CAS  Article  Google Scholar 

  5. 5.

    Cavalli R, Trotta F, Tumiatti W. Cyclodextrin-based nanosponges for drug delivery. J Incl Phenom Macrocycl Chem. 2006;56:209–13.

    CAS  Article  Google Scholar 

  6. 6.

    Sherje AP, Dravyakar BR, Kadam D, Jadhav M. Cyclodextrin-based nanosponges: a critical review. Carbohydr Polym. 2017;173:37–49.

    CAS  Article  Google Scholar 

  7. 7.

    F Trotta, W Tumiatti, Cross-linked polymers based on cyclodextrins for removing polluting agents, US20050154198A1, 2002.

  8. 8.

    Shende PK, Trotta F, Gaud RS, Deshmukh K, Cavalli R, Biasizzo M. Influence of different techniques on formulation and comparative characterization of inclusion complexes of ASA with β-cyclodextrin and inclusion complexes of ASA with PMDA cross-linked β-cyclodextrin nanosponges. J Incl Phenom Macrocycl Chem. 2012;74:447–54.

    CAS  Article  Google Scholar 

  9. 9.

    F Trotta, V Tumiatti, R Cavalli, C Maria, R Barbara, M Giovanni, et al., Cyclodextrin-based nanosponges as a vehicle for antitumoral drugs, WO2009003656A1, 2007.

  10. 10.

    Lockhart JN, Stevens DM, Beezer DB, Kravitz A, Harth E. Dual drug delivery of tamoxifen and quercetin: Regulated metabolism for anticancer treatment with nanosponges. J Control Release. 2015;220(Pt B):751–7.

    CAS  Article  Google Scholar 

  11. 11.

    Swaminathan S, Cavalli R, Trotta F, Ferruti P, Ranucci E, Gerges I, et al. In vitro release modulation and conformational stabilization of a model protein using swellable polyamidoamine nanosponges of β-cyclodextrin. J Incl Phenom Macrocycl Chem. 2010;68:183–91.

    CAS  Article  Google Scholar 

  12. 12.

    Owen RT. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic. Drugs Today. 2007;43:249–58.

    CAS  Article  Google Scholar 

  13. 13.

    Janicak PG, Winans EA, Paliperidone ER. a review of the clinical trial data. Neuropsychiatr Dis Treat. 2007;3:869–97. http://www.ncbi.nlm.nih.gov/pubmed/19300622.

    CAS  Article  Google Scholar 

  14. 14.

    Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Kreyenbuhl, American Psychiatric Association, Steering Committee on Practice Guidelines, Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161:1–56. http://www.ncbi.nlm.nih.gov/pubmed/15000267.

    Article  Google Scholar 

  15. 15.

    Kozielska M, Johnson M, Pilla Reddy V, Vermeulen A, Li C, Grimwood S, et al. Pharmacokinetic-pharmacodynamic modeling of the D2 and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats. Pharm Res. 2012;29:1932–48.

    CAS  Article  Google Scholar 

  16. 16.

    Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989;251:238–46.

    CAS  Google Scholar 

  17. 17.

    Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153:466–76.

    CAS  Article  Google Scholar 

  18. 18.

    Sherje A, Londhe V. Inclusion complexes of hydroxy Propyl-β-cyclodextrin and paliperidone: preparation and characterization. Curr Drug Discov Technol. 2014;11:271–8.

    CAS  Article  Google Scholar 

  19. 19.

    Sherje AP, Londhe V. Ternary inclusion complex of paliperidone with β-cyclodextrin and hydrophilic polymer for solubility and dissolution enhancement. J Pharm Innov. 2015;10:324–34.

    Article  Google Scholar 

  20. 20.

    Shende P, Kulkarni YA, Gaud RS, Deshmukh K, Cavalli R, Trotta F. F. Caldera, Acute and repeated dose toxicity studies of different β-cyclodextrin-based nanosponge formulations. J Pharm Sci. 2015;104:1856–63.

    CAS  Article  Google Scholar 

  21. 21.

    F Trotta, Pravin Shende, Method for preparing dextrin nanosponges, WO/2012/147069, 2012.

Download references

Acknowledgements

We are thankful to Cadila Pharmaceuticals Ltd, India and Gangwal Chemicals Pvt. Ltd., Mumbai, India for gift sample of Paliperidone and β-CD, respectively.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Atul P. Sherje.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sherje, A.P., Surve, A. & Shende, P. CDI cross-linked β-cyclodextrin nanosponges of paliperidone: synthesis and physicochemical characterization. J Mater Sci: Mater Med 30, 74 (2019). https://doi.org/10.1007/s10856-019-6268-0

Download citation